Pediatric psychopharmacological research in the post EU regulation 1901/2006 era-Is there a will and a way? experience and perspectives of lay and expert representatives in Germany

Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie

Volumn 42, Issue 6, 2014, Pages 441-449

  Schmäl, Christine ^a   Becker, Katja ^b   Berg, Ruth ^a   Brünger, Michael ^c   Lehmkuhl, Gerd ^d   Oehler, Klaus Ulrich ^e   Ruppert, Thorsten ^f   Staudter, Claus ^a,g   Trott, Götz Erik ^h   Dittmann, Ralf W ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c Department of Child and Adolescent Psychiatry Psychosomatics and Psychotherapy Pfalz Institute   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e Office for Child and Adolescent Psychiatry   (Germany)

^f VFA DIE FORSCHENDEN PHARMA UNTERNEHMEN   (Germany)

^g Ludwigshafen Association for Attention Deficit Hyperactivity Disorder   (Germany)

^h Child and Adolescent Psychiatry   (Germany)

Author keywords

Marketing authorization; Pediatric investigation plan; Psychopharmacological research clinical studies; Vulnerable pediatric populations

Indexed keywords

PSYCHOTROPIC AGENT;

ARTICLE; CHILD PSYCHIATRY; CHILD WELFARE; CLINICAL TRIAL (TOPIC); DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; EUROPEAN; GROUPS BY AGE; HUMAN; LAW; MENTAL DISEASE; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; ADOLESCENT; CHILD; COOPERATION; DRUG APPROVAL; EUROPEAN UNION; GERMANY; INTERDISCIPLINARY COMMUNICATION; LEGISLATION AND JURISPRUDENCE; MENTAL DISORDERS; OFF LABEL DRUG USE;

ADOLESCENT; ADOLESCENT PSYCHIATRY; CHILD; CHILD PSYCHIATRY; CLINICAL TRIALS AS TOPIC; COOPERATIVE BEHAVIOR; DRUG APPROVAL; DRUG INDUSTRY; EUROPEAN UNION; GERMANY; HUMANS; INTERDISCIPLINARY COMMUNICATION; MENTAL DISORDERS; OFF-LABEL USE; PSYCHOTROPIC DRUGS;

EID: 84908383302     PISSN: 14224917     EISSN: None     Source Type: Journal    
DOI: 10.1024/1422-4917/a000322     Document Type: Article

References (11)

1. Bliznak, L., Berg, R., Häge, A. & Dittmann, R. W. (2013). High rate of noneligibility: Methodological factors impacting on recruitment for a multicentre, double-blind study of paediatric patients with major depressive disorder. Pharmacopsychiatry, 46, 23-28. doi 10.1055/s-0032-1314806
2. Dalsgaard, S., Nielsen, H. S. & Simonsen, M. (2013). Five-fold increase in national prevalence rates of attention-deficit/hyper-activity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: A Danish register-based study. Journal of child and adolescent psychopharmacology, 23, 432-439. doi 10.1089/cap.2012.0111
3. Kölch, M., Allroggen, M. & Fegert, J. M. (2009). Off-Label-Use von Psychopharmaka in der Kinder-und Jugendpsychiatrie [Off-label use in child and adolescent psychiatry. An ongoing ethical, medical and legal problem]. Nervenarzt, 80, 789-796. doi 10.1007/s00115-009-2727-z
4. Lehmann, B. (2008). Regulation (EC) No 1901/2006 on medicinal products for paediatric use & clinical research in vulnerable populations. Child and Adolescent Psychiatry and Mental Health, 2, 37-43. doi 10.1186/1753-2000-2-37
5. Parker, G., Anderson, I. M. & Haddad, P. (2003). Clinical trials of antidepressant medications are producing meaningless results. The British Journal of Psychiatry, 183, 102-104.
6. Russ, H., Busta, S., Riedel, A., Zöllner, G. & Jost, B. (2009). Evaluation of clinical trials by Ethics Committees in Germany: Experience of applicants with the review of requests for opinion of the Ethic Committees-Results of a survey among members of the German Association of Research-Based Pharmaceutical Companies (vfa). German Medical Science, 7, Doc07-Doc07.
7. Tan, J. O. & Kölch, M. (2008). The ethics of psychopharmaco-logical research in legal minors. Child and Adolescent Psychiatry and Mental Health, 2, 39-52. doi 10.1186/1753-2000-2-39
8. The European Agency for the Evaluation of Medicinal Products-Evaluation of Medicines for Human Use. (2000). Note for guidance on clinical investigation of medicinal products in the pae-diatric population (CPMP/ICH/2711/99) London. EMEA 2000.
9. Wong, I.C., Murray, M.L., Camilleri-Novak, D. & Stephens, P. (2004). Increased prescribing trends of paediatric psychotropic medications. Archives of Disease in Childhood, 89, 1131-1132. doi 10.1136/adc.2004.050468
10. Zito, J. M., Derivan, A. T., Kratochvil, C. J., Safer, D. J., Fegert, J. M. & Greenhill, L. L. (2008). Off-label psychopharmacolog-ic prescribing for children: History supports close clinical monitoring. Child and Adolescent Psychiatry and Mental Health, 2, 24-34. doi 10.1186/1753-2000-2-24
11. Zito, J. M., Safer, D. J., de Jong-van den Berg, L. T., Janhsen, K., Fegert, J. M., Gardner, J. F.,.. Valluri, S. C. (2008). A three-country comparison of psychotropic medication prevalence in youth. Child and Adolescent Psychiatry and Mental Health, 2, 26. doi 10.1186/1753-2000-2-26